BR9915636A - Método para promover secreções cervicais e vaginais - Google Patents

Método para promover secreções cervicais e vaginais

Info

Publication number
BR9915636A
BR9915636A BR9915636-9A BR9915636A BR9915636A BR 9915636 A BR9915636 A BR 9915636A BR 9915636 A BR9915636 A BR 9915636A BR 9915636 A BR9915636 A BR 9915636A
Authority
BR
Brazil
Prior art keywords
triphosphate
vaginal secretions
cervical
treatment
vaginal
Prior art date
Application number
BR9915636-9A
Other languages
English (en)
Inventor
William Pendergast
Sammy R Shaver
David J Drutz
Janet L Rideout
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of BR9915636A publication Critical patent/BR9915636A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Abstract

"MéTODO PARA PROMOVER SECREçõES CERVICAIS E VAGINAIS". A presente invenção refere-se a um método de estimular secreções cervicais e vaginais em um mamífero por tratamento com agonistas purinérgicos P2Y~ 2~ e/ou P2Y~ 4~. é discutido o tratamento de secura vaginal associada com menopausa, quimioterapia, e vários estados de doença bem como o tratamento de dor vulvar. Agonistas receptores purinérgicos adequados incluem trifosfato de nucleotídeos tais como 5-trifosfato de uridina, 5'-trifosfato de citidina e 5'trifosfato de adenosina, polifosfatos de nucleotídeo, tais como tetrafosfato de P^ 1^, p^ 4^ -di(uridina-5') e seus análogos. Esses agonistas receptores purinérgicos são úteis para estimular secreções cervicais e vaginais e no tratamento de secura vaginal em mamíferos.
BR9915636-9A 1998-11-25 1999-11-19 Método para promover secreções cervicais e vaginais BR9915636A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/199,912 US6462028B2 (en) 1997-07-25 1998-11-25 Method of promoting cervical and vaginal secretions
PCT/US1999/027634 WO2000030629A2 (en) 1998-11-25 1999-11-19 Method of promoting cervical and vaginal secretions

Publications (1)

Publication Number Publication Date
BR9915636A true BR9915636A (pt) 2002-12-24

Family

ID=22739534

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915636-9A BR9915636A (pt) 1998-11-25 1999-11-19 Método para promover secreções cervicais e vaginais

Country Status (12)

Country Link
US (2) US6462028B2 (pt)
EP (1) EP1133304A2 (pt)
JP (1) JP2003524609A (pt)
KR (1) KR20010101066A (pt)
CN (1) CN1348378A (pt)
AU (1) AU764452B2 (pt)
BR (1) BR9915636A (pt)
CA (1) CA2352262A1 (pt)
ID (1) ID29801A (pt)
NO (1) NO20012555L (pt)
WO (1) WO2000030629A2 (pt)
ZA (1) ZA200104310B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
JP3723227B2 (ja) 1997-07-25 2005-12-07 インスパイアー ファーマシューティカルズ，インコーポレイティド ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
US7256183B2 (en) 2001-11-06 2007-08-14 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
EP1348466A3 (en) * 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US20030162769A1 (en) * 2002-02-26 2003-08-28 Easterling W. Jerry Composition and method for treating vulvodynia
US20050176782A1 (en) * 2002-02-26 2005-08-11 Easterling W. J. Medicament and method for treating vulodynia
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2004037167A2 (en) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methods of treating dry eye disease with lantibiotics
US7056889B2 (en) * 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
GB0312845D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of componds in medicine
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US6949067B1 (en) * 2004-05-11 2005-09-27 Dann Jeffrey A Device and method for enhancing female sexual stimulation
US8147399B2 (en) 2004-05-11 2012-04-03 Gloth David A Device and method for applying a biocompatible substance to a female stimulation device
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
DE102004054552A1 (de) 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
US7368439B2 (en) 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
WO2014057096A1 (en) * 2012-10-12 2014-04-17 Inoflex Ab Composition for alleviating conditions associated with vaginal dryness
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639562A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
JPH05346549A (ja) 1992-04-17 1993-12-27 Canon Inc 走査光学装置
US5482706A (en) * 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
IT1277373B1 (it) * 1995-07-28 1997-11-10 Consiglio Nazionale Ricerche Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
US6423694B1 (en) 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
DE69736468T2 (de) 1996-03-27 2007-03-29 Inspire Pharmaceuticals, Inc. Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) * 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
JP4531867B2 (ja) 1997-02-06 2010-08-25 インスパイアー ファーマシューティカルズ，インコーポレイティド 一定のジヌクレオチドおよび粘膜繊毛クリアランスおよび繊毛運動頻度のモジュレーターとしてのそれらの使用
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
JP3723227B2 (ja) * 1997-07-25 2005-12-07 インスパイアー ファーマシューティカルズ，インコーポレイティド ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women

Also Published As

Publication number Publication date
NO20012555D0 (no) 2001-05-23
EP1133304A2 (en) 2001-09-19
AU1741200A (en) 2000-06-13
JP2003524609A (ja) 2003-08-19
AU764452B2 (en) 2003-08-21
CA2352262A1 (en) 2000-06-02
US20080214490A1 (en) 2008-09-04
US6462028B2 (en) 2002-10-08
US20020013289A1 (en) 2002-01-31
WO2000030629A3 (en) 2001-06-07
NO20012555L (no) 2001-07-24
CN1348378A (zh) 2002-05-08
ID29801A (id) 2001-10-11
WO2000030629A2 (en) 2000-06-02
KR20010101066A (ko) 2001-11-14
ZA200104310B (en) 2002-10-24

Similar Documents

Publication Publication Date Title
BR9915636A (pt) Método para promover secreções cervicais e vaginais
BR9810436A (pt) Processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo
EP0496617B1 (en) Adenosine kinase inhibitors
Rahim et al. Synthesis and anti-herpes virus activity of 2 ‘-deoxy-4 ‘-thiopyrimidine nucleosides
Parker et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate
NZ333983A (en) Method of treating sinusitis with uridine triphosphates and related compounds
DE60122285D1 (de) Methonocarbacycloalkylanaloga von nucleosiden
BR0114837A (pt) nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
NZ601660A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
BRPI0518984A2 (pt) anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal
ATE196912T1 (de) Propargylethoxyamino nucleotide
BRPI0515279A (pt) preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
KR20050059975A (ko) β-2'- 또는 3'-할로뉴클레오시드
BR0316407A (pt) Derivados de nucleosìdeo antiviral
BR0114089A (pt) Derivados de purina
JP2005508297A5 (pt)
AU1359992A (en) Adenosine kinase inhibitors
JP2005532254A5 (pt)
MXPA04004215A (es) Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
Ipata et al. Metabolic interplay between intra-and extra-cellular uridine metabolism via an ATP driven uridine–UTP cycle in brain
DK380085A (da) Sonder omfattende modificerede adeningrupper, fremgangsmaade til deresfremstilling samt deres anvendelser
HUP0300219A2 (hu) L-nukleozidokat, L-nukleotidokat és analógjaikat tartalmazó készítmények és alkalmazásuk
US3804827A (en) 1-beta-d-arabinofuranosylcytosine-3',5'-cyclic phosphate and derivatives thereof
DE69131796T2 (de) Analoge des ajca-ribosids
BRPI0816498A2 (pt) combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.